MSB Trading - Aug 2020 on, page-861

No need to get antsy. I was just asking a question. My takeaway is that they have a few concerns over the trial designs and may need another, although you are right they need a treatment and could always approve it and then go with a post-approval follow up trial or the like. The other issue is question marks about batch consistency and whether all batches have the same efficacy. Hard to tell which way this might go - stem cells being generally new, issues around consistency and efficacy due to trial design, but at the same time unmet medical needs. I think people buying in mid to high $4 were doing it in FOMO and not because they'd researched the company and where the science is at currently.

My sentiment is buy but at a price that leaves a greater margin for error due to the risk. Ok if you were in from a long time ago, but for a lot of others it's too risky.